Generate Biomedicines IPO Turns Heads

Generate Biomedicines IPO highlights AI-driven drug discovery, strong backing, promising pipeline, and investor confidence signals.
FierceBiotech

Generate raises $273M—$100M less than previous round—but a huge bounty

Flagship Pioneering-founded Generate Biomedicines is tacking on a gigantic $273 million in series C funds, though the haul didn't reach the heights of the biotech’s previous $370 million raise back in ...
pharmaphorum

AI firm Generate signs $1bn discovery deal with Novartis

Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis. The wide-ranging deal, worth up to $1 billion, ...
Yahoo Finance

Generate Capital Closes $85 Million Community Solar Tax Equity Fund with KeyState, Expanding Leadership in Distributed Clean Energy Financing

SAN FRANCISCO, Oct. 9, 2025 /PRNewswire/ -- Generate Capital, PBC ("Generate"), a leading infrastructure investment firm, today announced the closing of an $85 million tax equity commitment with ...
Reuters

Generate Biomedicines shares fall in weak Nasdaq debut for drug developer

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...
Forbes

Generate Biomedicines

Generate Biomedicines is setting out to “program” medicine by almost instantaneously creating models of new proteins. Launched out of life sciences venture firm Flagship Pioneering, it raised a large ...